On December 14, 2017, Ekso announced that "the Company's internal control over financial reporting as of December 31, 2016 should no longer be relied upon and that a material weakness in the Company's internal control over financial reporting existed as of such date." Following this news, Ekso's share price fell $0.15 per share, or 6.17%, to close at $2.28 on December 15, 2017.

On December 27, 2017, post-market, Ekso filed its amended annual report for 2016 and amended quarterly reports for the first three quarters of 2017. The following trading day, Ekso's share price fell $0.34 per share, or 13.2%, to close at $2.23 per share on December 28, 2017.

The Complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) there was a material weakness in Ekso's internal control over financial reporting and (2) Ekso's disclosure controls and procedures were not effective. As a result, Defendants public statements were materially false and misleading throughout the Class Period.

If you purchased or otherwise acquired Ekso securities and suffered a loss, continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Ekso Bionics lawsuit, please go to www.bespc.com/ekso. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.

Contact

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

SOURCE: Bragar Eagel & Squire, P.C.

ReleaseID: 490071

"/> Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Ekso Bionics Holdings, Inc. (EKSO) and Encourages Investors to Contact the Firm « MarketersMedia – Press Release Distribution Services – News Release Distribution Services
Great News! MarketersMedia is officially entering into a long-term partnership with Vertical News Network.
Learn More
How It Works? Plans & Pricing Our Distributions Newsroom Info Hub Sign Up Sign In Send Press Release Contact Sales
Contact Sales Sign Up Your Account Send Press Release
MarketersMEDIA / Newsroom / Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Ekso Bionics Holdings, Inc. (EKSO) and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Ekso Bionics Holdings, Inc. (EKSO) and Encourages Investors to Contact the Firm

Share This Press Release

NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of all persons or entities who purchased or otherwise acquired Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) securities between March 15, 2017 and December 27, 2017 (the "Class Period"). Investors have until March 5, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

On December 14, 2017, Ekso announced that "the Company's internal control over financial reporting as of December 31, 2016 should no longer be relied upon and that a material weakness in the Company's internal control over financial reporting existed as of such date." Following this news, Ekso's share price fell $0.15 per share, or 6.17%, to close at $2.28 on December 15, 2017.

On December 27, 2017, post-market, Ekso filed its amended annual report for 2016 and amended quarterly reports for the first three quarters of 2017. The following trading day, Ekso's share price fell $0.34 per share, or 13.2%, to close at $2.23 per share on December 28, 2017.

The Complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) there was a material weakness in Ekso's internal control over financial reporting and (2) Ekso's disclosure controls and procedures were not effective. As a result, Defendants public statements were materially false and misleading throughout the Class Period.

If you purchased or otherwise acquired Ekso securities and suffered a loss, continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Ekso Bionics lawsuit, please go to www.bespc.com/ekso. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.

Contact

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

SOURCE: Bragar Eagel & Squire, P.C.

ReleaseID: 490071

NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of all persons or entities who purchased or otherwise acquired Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) securities between March 15, 2017 and December 27, 2017 (the "Class Period"). Investors have until March 5, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

On December 14, 2017, Ekso announced that "the Company's internal control over financial reporting as of December 31, 2016 should no longer be relied upon and that a material weakness in the Company's internal control over financial reporting existed as of such date." Following this news, Ekso's share price fell $0.15 per share, or 6.17%, to close at $2.28 on December 15, 2017.

On December 27, 2017, post-market, Ekso filed its amended annual report for 2016 and amended quarterly reports for the first three quarters of 2017. The following trading day, Ekso's share price fell $0.34 per share, or 13.2%, to close at $2.23 per share on December 28, 2017.

The Complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) there was a material weakness in Ekso's internal control over financial reporting and (2) Ekso's disclosure controls and procedures were not effective. As a result, Defendants public statements were materially false and misleading throughout the Class Period.

If you purchased or otherwise acquired Ekso securities and suffered a loss, continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Ekso Bionics lawsuit, please go to www.bespc.com/ekso. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.

Contact

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

SOURCE: Bragar Eagel & Squire, P.C.

ReleaseID: 490071

Source URL: https://marketersmedia.com/bragar-eagel-squire-p-c-reminds-investors-that-a-class-action-lawsuit-has-been-filed-against-ekso-bionics-holdings-inc-ekso-and-encourages-investors-to-contact-the-firm/303723

Source: AccessWire

Release ID: 303723

Latest Releases

Our Client

Subscribe and Recieve exclusive insider tips and tricks on Press Release.

Follow Us

Copyright © 2012 - 2018 MarketersMedia – Press Release Distribution Services – News Release Distribution Services. All Rights Reserved.

Powered by Semantics BigData Analytics (SBDA).